AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc (“Swarmer” or the “Company”) (Nasdaq: SWMR), a drone autonomy software company which has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced financial results for the quarter ended March 31, 2026 (“Q1 2026”), and discussed recent business developments. Management CommentarySwarmer President & U.S. CEO Alex Fink stated: “The first quarter of 2026 represented an important step forward for Swarmer as we completed our initial public offering, strengthened our leadership team and continued to expand our presence within the autonomous systems ecosystem. These milestones support our ability to pursue a rapidly expanding market, as demand for autonomous and collaborative unmanned systems continues to accelerate amid rising deployment...

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026. Financial Highlights & Recent DevelopmentsResearch and development expense was $554 thousand, a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines. Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia.“During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while...

Total Revenues of $48.5 million, at Top End of Guidance Range Trailing Twelve-Month Impressions Up Approximately 12% Year Over Year, Driven by Continued Screen-to-Digital Shift AIC Revenues Increased Approximately 103% Year Over Year Delivered Positive Operating Cash Flow for Tenth Consecutive Quarter Strong Customer Response and Growing Atlas MATRIX Backlog Reinforce Expansion of Digital Production at Scale Enters Second Quarter with Strengthening Momentum, Improved Visibility and Continued AIC Transition ROSH-HA`AYIN, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a global leader in sustainable, on-demand, digital fashion and textile production, today reported financial results for the first quarter ended March 31, 2026. The results reflect the Company’s continued progress...

– Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer –  – First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 – – Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia – – Announced Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Injury Repair – – U.S. Department of Defense funding for procurement of bioengineered blood vessels – – Major milestone upcoming: Top-line interim results from V012 Phase 3 study in hemodialysis access – -Conference call today at 8:00 am ET – DURHAM, N.C., May 13, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc....

Forecasting Sequential Quarter Over Quarter Revenue and Margin Growth Throughout the Year with Second Quarter 2026 at a Company Record of $455 Million MIGDAL HAEMEK, Israel, May 13, 2026 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ/TASE: TSEM) reports today its results for the first quarter ended March 31, 2026. First Quarter of 2026 Results OverviewRevenue for the first quarter of 2026 was $414 million as compared to $358 million for the first quarter of 2025, representing 15% year-over-year revenue growth. Gross profit and operating profit for the first quarter of 2026 were $111 million and $65 million, respectively, compared to $73 million and $33 million in the first quarter of 2025, respectively, representing 52% gross profit growth and 96% operating profit growth. Net profit for the first quarter of 2026 was $65 million,...

Management will host an earnings webcast on Wednesday, May 13 at 8:30 a.m. ET TOKYO, May 13, 2026 (GLOBE NEWSWIRE) — CTW (Nasdaq: CTW) (“the Company”), a leading game platform company providing global access to web-based games through its flagship HTML5 platform, G123.jp, reports financial results for the six months ending January 31, 2026 (“1H26”), highlighting the resilience of its asset-light operating model, which drove significant improvement in segment profitability and Adjusted EBITDA despite modest year-over-year revenue softness. 1H26 Financial and Business HighlightsRevenue of $40.9 million in 1H26, a decline of 1% from $41.2 million in the six months ended January 31, 2025 (“1H25”)Segment profit increased 55% year-over-year and Adjusted EBITDA increased 16% year-over-year, demonstrating the flexibility of CTW’s asset-light...

– Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in severe asthma and CRSwNP – – End-of-Phase 2 meetings with FDA planned for mid-2026; Phase 3 initiations in both indications expected in Q1 2027 – – Phase 2 VENTURE trial in COPD ongoing; Company to cap further enrollment; data now expected in the second half of 2027 – – Upcoming data presentations at ATS and EAACI to further elaborate the clinical profile of verekitug – WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the first quarter ended March 31, 2026, and highlighted its continued progress in developing verekitug...

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline. “Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning...

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public offering of equity securities for gross proceeds of $431.3 million Cash, cash equivalents, and short-term investments of $82 million as of March 31, 2026, not including the subsequent financingWAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results. “The positive Phase 2 LOTUS trial results of abdakibart in HS, which demonstrated a deep and consistent clinical response across both HiSCR75...

Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026. “During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards restarting enrollment in the amended VERSATILE-003 Phase 3 trial. With regards to PDS01ADC, we have completed enrollment in the metastatic colorectal cancer trial, and the advanced castration resistant prostate cancer trial continues to recruit well”. Dr....